A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9-engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors.
Publication
, Conference
Pal, SK; Reimers, MA; Garmezy, B; Xu, W; Hoimes, CJ; Weinstein, M; Cullingford, EL; Ma, A; Williams, LM; Dar, H; Keegan, A; Srour, SA
Published in: JOURNAL OF CLINICAL ONCOLOGY
2024
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2024
Volume
42
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Pal, S. K., Reimers, M. A., Garmezy, B., Xu, W., Hoimes, C. J., Weinstein, M., … Srour, S. A. (2024). A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9-engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 42).
Pal, Sumanta Kumar, Melissa Andrea Reimers, Benjamin Garmezy, Wenxin Xu, Christopher J. Hoimes, Michael Weinstein, Erika L. Cullingford, et al. “A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9-engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 42, 2024.
Pal SK, Reimers MA, Garmezy B, Xu W, Hoimes CJ, Weinstein M, et al. A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9-engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors. In: JOURNAL OF CLINICAL ONCOLOGY. 2024.
Pal, Sumanta Kumar, et al. “A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9-engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors.” JOURNAL OF CLINICAL ONCOLOGY, vol. 42, no. 16, 2024.
Pal SK, Reimers MA, Garmezy B, Xu W, Hoimes CJ, Weinstein M, Cullingford EL, Ma A, Williams LM, Dar H, Keegan A, Srour SA. A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9-engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors. JOURNAL OF CLINICAL ONCOLOGY. 2024.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2024
Volume
42
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences